<DOC>
	<DOCNO>NCT01656629</DOCNO>
	<brief_summary>Osteoporosis important health problem rapidly-aging demographic . Fragility fracture devastate consequence osteoporosis . The common treatment approach osteoporosis inhibition bone resorption drug like alendronate ( ALN ) . Parathyroid hormone ( PTH ) stimulate bone formation anabolic drug available . Dual therapy ALN PTH effective single-drug therapy preventing fracture . Bone progenitor cell ( MSCs ) recruit site bone remodel growth factor call Transforming Growth Factor Beta ( TGF-β1 ) release bone . Different osteoporosis medicine may differ effect process . The effect ALN versus PTH bone progenitor recruitment human unknown . This randomize , clinical trial ALN , PTH , calcium vitamin D post-menopausal woman low bone mass . Women treat 3 month ALN PTH calcium vitamin D. Data collect include bone biopsy histomorphometry micro compute tomography ( µCT ) , bone marrow aspirate molecular study , peripheral blood detect circulate bone progenitor cell dual X-ray absorptiometry . The investigator hypothesize human , PTH 1 ) increase bone progenitor number , 2 ) enhance recruitment bone progenitor cell bone resorption site , 3 ) increase bone progenitor number peripheral circulation . Furthermore , investigator hypothesize ALN treatment opposite effect . Understanding difference bone progenitor cell activity recruitment osteoporosis therapy provide mechanistic rationale effective use PTH anti-resorptive drug osteoporosis treatment .</brief_summary>
	<brief_title>Stem Cell Recruitment Osteoporosis Therapy</brief_title>
	<detailed_description />
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal woman age 5080 year T score &lt; 2.5 lumbar spine , total hip femoral neck dual xray absorptiometry ( DXA ) OR T score &lt; 1.5 personal family history fracture Previous use bisphosphonates PTH ; current estrogen therapy ; osteoporosis therapy past 6 month Metabolic bone disease osteoporosis BMI &lt; 18 Weight &gt; 325 lbs Current smoking current alcohol use exceed 3 unit alcohol daily Use medication know affect bone metabolism Renal disease , history kidney stone hypercalciuria Hypo hyperparathyroidism ; hypo hypercalcemia Serum vitamin D level &lt; 20 ng/dL Refusal adjust dietary calcium &lt; 750mg ( i.e . two serving per day calcium rich food ) History bone marrow organ transplant History malignancy radiation bone History esophageal stricture , dysmotility severe reflux disease Gastrointestinal malabsorption Use digoxin Need chronic anticoagulation therapy Coumadin , heparin low molecular weight heparin inability discontinue antiplatelet medication Bleeding diathesis ; hemoglobin ≤ 12.5 g/dL ( American Red Cross cutoff donate blood ) International normalize ratio ( INR ) pro time &gt; 1.1 activate partial thromboplastin time ( APT ) T ratio &gt; 1.2 Platelets &lt; 150K/cu mm Cellulitis site iliac crest History allergy medication use bone biopsy ( demeclocycline , lidocaine ) Inability understand provide inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>